Allogenic Mesenchymal Stem Cells as a Treatment for Equine Degenerative Joint Disease: A Pilot Study

Background: The ability to repair tissue via percutaneous means may allow interventional pain physicians to manage a wide variety of diseases including peripheral joint injuries and osteoarthritis. This review will highlight the developments in cellular medicine that may soon permit interventional pain management physicians to treat a much wider variety of clinical conditions and highlight an interventional case study using these technologies Objective: To determine if isolated and expanded human autologous mesenchymal stem cells could effectively regenerate cartilage and meniscal tissue when percutaneously injected into knees. Design: Case Study Setting: Private Interventional Pain Management practice. Methods: An IRB approved study with a consenting volunteer in which mesenchymal stem cells were isolated and cultured ex-vivo from bone marrow aspiration of the iliac crest. The mesenchymal stem cells were then percutaneously injected into the subject’s knee with MRI proven degenerative joint disease. Preand post-treatment subjective visual analog pain scores, physical therapy assessments, and MRIs measured clinical and radiographic changes. Results: At 24 weeks post-injection, the patient had statistically significant cartilage and meniscus growth on MRI, as well as increased range of motion and decreased modified VAS pain scores. Conclusion: The described process of autologous mesenchymal stem cell culture and percutaneous injection into a knee with symptomatic and radiographic degenerative joint disease resulted in significant cartilage growth, decreased pain and increased joint mobility in this patient. This has significant future implications for minimally invasive treatment of osteoarthritis and meniscal injury. Key words: autologous mesenchymal stem cells, osteoarthritis, knee, cartilage

Download Full-text

Combined therapies with exercise, ozone and mesenchymal stem cells improve the expression of HIF1 and SOX9 in the cartilage tissue of rats with knee osteoarthritis

Physiology International ◽

10.1556/2060.2020.00024 ◽

2020 ◽

Vol 107 (2) ◽

pp. 231-242

Author(s):

Sara Asadi ◽

Parvin Farzanegi ◽

Mohammad Ali Azarbayjani

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Knee Osteoarthritis ◽

Combined Therapy ◽

Hypoxia Inducible Factor ◽

Degenerative Joint Disease ◽

Exercise Group ◽

Joint Disease ◽

Cartilage Tissue ◽

Knee Oa

AbstractPurposeKnee osteoarthritis (OA) is a common type of degenerative joint disease which decreases the quality of life. Sex-determining region Y box 9 (SOX9) and hypoxia-inducible factor-1 (HIF1) are considered as the key regulators of OA. We investigated the effect of combined therapies with mesenchymal stem cells (MSCs), ozone (O3) and exercise training on SOX9 and HIF1 expression in the cartilage of rats with knee OA.MethodsKnee OA was induced by surgical method. OA rats were divided into model, MSCs, ozone, exercise, MSCs + ozone, MSCs + exercise, ozone + exercise and MSCs + ozone + exercise groups. Rats in the MSCs group received intraarticular injection of 1 × 106 cells/kg. Rats in the ozone group received O3 at the concentration of 20 μg/mL, once weekly for 3 weeks. Rats in the exercise group were trained on rodent treadmill three times per week. 48 hours after the programs, cartilage tissues were isolated and the expression of SOX9 and HIF1 was determined using Real-Time PCR.ResultsSignificant differences were found in the expression of SOX9 and HIF1 between groups (P < 0.0001). Although combined therapies with exercise, MSCs and O3 significantly increased the expression of SOX9 and HIF1 in the cartilage tissue of rats with knee OA, combination of exercise with O3 was significantly more effective compared to the other combined therapies (P < 0.001).ConclusionsCombined therapy with exercise, MSCs and O3 significantly increased the expression of SOX9 and HIF1 genes in the cartilage of rats with knee OA; however, exercise + O3 was significantly more effective.

Download Full-text

Treatment of equine degenerative joint disease with autologous peripheral blood-derived mesenchymal stem cells: a case report

Vlaams Diergeneeskundig Tijdschrift ◽

10.21825/vdt.v81i1.18372 ◽

2012 ◽

Vol 81 (1) ◽

pp. 11-15

Author(s):

J. H. Spaas ◽

M. Oosterlinck ◽

S. Broeckx ◽

M. Dumoulin ◽

J. Saunders ◽

...

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Peripheral Blood ◽

Positive Response ◽

Single Case ◽

Degenerative Joint Disease ◽

Joint Disease ◽

Medical Treatments ◽

Autologous Mesenchymal Stem Cells ◽

Stem Cell Treatment

A 5-year-old German Warmblood stallion with chronic lameness, attributable to degenerative joint disease (DJD) of the pastern joint unresponsive to medical treatments, was treated with autologous mesenchymal stem cells (MSC). These MSC were isolated from the peripheral blood (PB) of the patient and injected into the pastern joint, at a concentration of 2.5x106 cells, twice with an 8-week interval. The positive response to this stem cell treatment was documented by visual gait evaluation as well as objective pressure plate analyses. This paper is the first to describe the use of autologous PB-derived MSC to treat a horse suffering from chronic DJD. The favorable outcome of this single case may stimulate further research on the use of equine peripheral blood as a source of autologous MSC in equine regenerative medicine.

Download Full-text

Effect of mesenchymal stem cells combined with chondroitin sulfate in osteoarthritis

10.21203/rs.3.rs-23610/v1 ◽

2020 ◽

Author(s):

Saúl Pérez-Castrillo ◽

María Luisa González-Fernández ◽

Jessica Álvarez-Suárez ◽

Jaime Sánchez-Lázaro ◽

Marta Esteban-Blanco ◽

...

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Chondroitin Sulfate ◽

Inflammatory Cytokines ◽

Degenerative Joint Disease ◽

Joint Disease ◽

Promising Alternative ◽

Cell Based Therapy ◽

Therapy Strategy ◽

Pro Inflammatory Cytokines

Abstract Introduction: Osteoarthritis (OA) is a degenerative joint disease affecting the whole joint structure. Many authors have focused on the factors responsible for the development of inflammatory processes involved in OA. Adipose tissue-derived mesenchymal stem cells (ASCs) represent a promising alternative of cell-based therapy strategy in the treatment of OA which could be combined with any drugs. Chondroitin sulfate plays a protective role in the joint based on the decrease of pro-inflammatory cytokines, thus having an important role in the activation and inhibition of metabolic pathways in chondrocytes.Aims: In this study, the effectiveness of chondroitin sulfate and ASCs in the treatment of knee OA have also been evaluated.Materials: Cytokines and factors which are involved in OA as well as specific cartilage gene expression after adding ASCs and chondroitin sulfate have been discussed in detail.Results: Our results show a decrease in the expression of all genes related to the pro-inflammatory cytokines analysed. Although there was no increase in the expression of the specific genes of the cartilage matrix, such as collagen type II and aggrecan.Conclusions: This study show the effectiveness of association of ASCs and chondroitin sulfate for the treatment of OA.

Download Full-text

Current Perspectives in Mesenchymal Stem Cell Therapies for Osteoarthritis

Stem Cells International ◽

10.1155/2014/194318 ◽

2014 ◽

Vol 2014 ◽

pp. 1-13 ◽

Cited By ~ 41

Author(s):

Baldur Kristjánsson ◽

Sittisak Honsawek

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Cartilage Regeneration ◽

Degenerative Joint Disease ◽

Joint Disease ◽

Ageing Population ◽

Cell Therapies ◽

Current Trends ◽

Multipotent Progenitor Cells ◽

Reduced Activity

Osteoarthritis (OA) is a degenerative joint disease most commonly occurring in the ageing population. It is a slow progressive condition resulting in the destruction of hyaline cartilage followed by pain and reduced activity. Conventional treatments have little effects on the progression of the condition often leaving surgery as the last option. In the last 10 years tissue engineering utilising mesenchymal stem cells has been emerging as an alternative method for treating OA. Mesenchymal stem cells (MSCs) are multipotent progenitor cells found in various tissues, most commonly bone marrow and adipose tissue. MSCs are capable of differentiating into osteocytes, adipocytes, and chondrocytes. Autologous MSCs can be easily harvested and applied in treatment, but allogenic cells can also be employed. The early uses of MSCs focused on the implantations of cell rich matrixes during open surgeries, resulting in the formation of hyaline-like durable cartilage. More recently, the focus has completely shifted towards direct intra-articular injections where a great number of cells are suspended and injected into affected joints. In this review the history and early uses of MSCs in cartilage regeneration are reviewed and different approaches in current trends are explained and evaluated.

Download Full-text